Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.
Bruce E Sands, David B Clemow, Geert D'Haens, Peter M Irving, Taku Kobayashi, Laurent Peyrin-Biroulet, Karen Samaan, Anil Gaur, Ravneet Arora, Kris Todd, Richard Moses, Axel Dignass
BACKGROUND: Mirikizumab, an anti-interleukin-23 monoclonal antibody targeting the p19 subunit, has shown efficacy in inducing and maintaining clinical remission in patients with moderately-to-severely active ulcerative colitis (UC). This report summarizes the final long-term outcomes from the LUCENT-3 open-label extension (OLE) through week (W)212 of continuous treatment.
METHODS: Among 868 participants who received mirikizumab induction therapy in the LUCENT clinical trial program, 544 achieved clinical response. Of these, 365 were rerandomized to mirikizumab maintenance, with 324 completing W52, 316 entering the OLE, and 182 completing the OLE (4 years of continuous treatment), resulting in 835.3 total patient years of exposure. These analyses include efficacy and safety data from the LUCENT-3 cohort, stratified by LUCENT-1 baseline biologic experience, W52 remitter, and W52 responder status on entering the OLE study. Outcomes were analyzed using modified nonresponder imputation, traditional nonresponder imputation, and observed cases (OC) to handle missing data.
RESULTS: At W212, W52 Maintenance Remitters showed 77.7% clinical, 77.7% corticosteroid-free (CSF), 81.3% endoscopic, 66.0% histologic-endoscopic mucosal (HEMR), 94.3% symptomatic, and 73.6% bowel urgency (BU) remission rates (OC); 67.9% achieved histologic-endoscopic mucosal improvement (HEMI), 97.1% sustained clinical response, and 92.9% achieved BU clinically meaningful improvement (CMI). At W212, W52 Maintenance Responders showed 68.7% clinical, 68.7% CSF, 70.2% endoscopic, 55.1% HEMR, 92.7% symptomatic, and 74.8% BU remission rates (OC). For W52 Maintenance Completers, reductions in stool frequency, rectal bleeding, bowel urgency, and abdominal pain from baseline were sustained to W212. W52 Maintenance Remitters and Responders achieved Inflammatory Bowel Disease Questionnaire (IBDQ; quality of life measure) response (70%) and remission (>66%) at W212. Across biologic failed and bionaive subgroups, efficacy results were generally similar. For over 160 weeks of OLE treatment in the safety population, no new safety signals emerged from long-term exposure compared with induction and maintenance treatment.
CONCLUSIONS: Mirikizumab provided sustained symptomatic, clinical, endoscopic, and histologic benefits over 4 years in responding patients with moderately-to-severely active UC, including those with prior biologic failure. These treatment goals, which are integral to comprehensive disease management, support the long-term use of mirikizumab.
KM 提取结果
0 个 Figure · 0 个 KM 面板
尚未提取到 KM 面板。其他 Figure(7,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。
Figure 1Figure 1 (A) LUCENT clinical trial program with LUCENT-3 patient flow pathways for the analyzed populations and (B) LUCENT clinical program patient disposition with treatment discontinuations. Response is defined as achieving a ≥2-point and ≥30% decrease in the MMS from induction baseline with RB of 0 or 1, or a ≥1-point decrease from baseline. a 1 patient was randomized but not dosed; 118 patients had eCOA transcription errors. Abbreviations: DBL, database lock; eCOA, electronic clinical outcome assessment; IV, intravenous; MIRI, mirikizumab; mITT, modified intent-to-treat; MMS, modified Mayo score; N , number of patients; NR, nonresponder; OL, open-label; PBO, placebo; Q4W, every 4 weeks; PBO, placebo; R, responder; RB, rectal bleeding; SC, subcutaneous; W, week.
非 KM Figure
Figure 2Figure 2 Mirikizumab maintains rates of clinical remission, CSF remission, endoscopic remission, bowel urgency remission, symptomatic remission, HEMR, and disease clearance at 4 years of continuous treatment in W52 Maintenance (A) Remitters and (B) Responders (NRI, mNRI, OC). The modified intent-to-treat population was used with NRI, mNRI, and OC methods for missing data. Responders: ≥30% and ≥2-point decrease from baseline in the composite clinical endpoint of the sum of ES, SF subscore, and RB subscore, and RB of 0 or 1, or a ≥1-point decrease from baseline. Remitters: MMS SF of 0 or SF of 1 with a ≥1-point decrease from baseline; RB of 0; and ES of 0 or 1. CSF remission: clinical remission with no CS use for ≥12 weeks prior to the endpoint of interest. Endoscopic remission: ES of 0 or 1 (excluding friability). HEMR: Geboes score ≤ 2B.0 and ES of 0 or 1 (excluding friability). Bowel urgency remission: Urgency NRS score of 0 or 1. Symptomatic remission: SF of 0 or SF of 1 with a ≥1-point decrease in MMS from baseline, and RB of 0. Disease clearance is defined as achieving symptomatic remission and HEMR. Abbreviations: CI, confidence interval; CS, corticosteroid; CSF, corticosteroid-free; ES, endoscopic subscore; HEMR, histologic-endoscopic mucosal remission; MMS, modified Mayo score; mNRI, modified nonresponder imputation; N , number of patients; NRI, nonresponder imputation; NRS, numeric rating scale; OC, observed case; RB, rectal bleeding; SF, stool frequency; W, week.
非 KM Figure
Figure 3Figure 3 Mirikizumab maintains rates of clinical remission, symptomatic remission, HEMR, and disease clearance at 4 years of continuous treatment in W52 Maintenance (A) Remitters and (B) Responders by biologic-failed and not-biologic-failed treatment status (NRI, OC). The modified intent-to-treat population was used with NRI methods for missing data. Responders: ≥30% and ≥2-point decrease from baseline in the composite clinical endpoint of the sum of ES, SF subscore, and RB subscore, and RB of 0 or 1, or a ≥1-point decrease from baseline. Remitters: MMS SF of 0 or SF of 1 with a ≥1-point decrease from baseline; RB of 0; and ES of 0 or 1. Biologic failed refers to prior inadequate response, loss of response, or intolerance to biologic therapy or Janus kinase inhibitors (tofacitinib) at LUCENT-1 induction baseline. Not biologic failed refers to not meeting the biologic-failed definition at LUCENT-1 induction baseline. Symptomatic remission: SF of 0 or SF of 1 with a ≥1-point decrease in MMS from baseline, and RB of 0. HEMR: Geboes score ≤ 2B.0 and ES of 0 or 1 (excluding friability). Disease clearance is defined as achieving symptomatic remission and HEMR. For subgroups, mNRI was not performed as the smaller N compromises the methodology. Abbreviations: CI, confidence interval; DC, disease clearance; ES, endoscopic subscore; HEMR, histologic-endoscopic mucosal remission; MMS, modified Mayo score; N , number of patients; NRI, nonresponder imputation; OC, observed case; RB, rectal bleeding; SF, stool frequency; W, week.
非 KM Figure
Figure 4Figure 4 Change from induction baseline in ulcerative colitis symptoms by visit through 4 years of continuous mirikizumab treatment in the mITT population (LUCENT-1), Mirikizumab Induction Responders (LUCENT-2), and W52 Maintenance Completers (LUCENT-3, open-label) for (A) bowel urgency, (B) SF, and (C) RB (MMRM). The mITT population was used with MMRM to estimate the LSM change from baseline. The LUCENT program is three separate studies with different study designs, and patients flow from one study to the next; thus, the patient population is changing across studies: LUCENT-1 (mITT), LUCENT-2 (Mirikizumab Induction Responders), LUCENT-3 (W52 Mirikizumab Maintenance Completers). See Figure 1 for patient flow and the current examined population that follows Mirikizumab Induction Responders through the LUCENT clinical program. The Urgency NRS (0- to 10-point severity scale with 0 denoting no urgency and 10 denoting the worst possible urgency, with a ≥3-point decrease considered CMI),15 MMS SF subscore [0 to 3 score; 0, normal; (1) 1 to 2 stools more than normal; (2) 3 to 4 stools more than normal; (3) ≥ 5 stools more than normal] and MMS RB subscore [0 to 3 score; 0, normal; (1) streaks of blood with stool less than half the time; (2) obvious blood with stool most of the time; (3) blood alone passed] measure changes in the respective symptom from the induction baseline. Based upon MMS study response definitions, a change of >1 point is considered a CMI for SF and RB. There currently is not a validated CMI change from baseline cutoff criteria. LSM was reported for each treatment group except for W0 of maintenance (‡; W12). Abbreviations: CMI, clinically meaningful improvement; IV, intravenous; LSM, least square mean; MIRI, mirikizumab; MMS, modified Mayo score; mITT, modified intent-to-treat; MMRM, mixed-effects model for repeated measures; N , number of patients; NRS, numeric rating scale; RB, rectal bleeding; SF, stool frequency; SC, subcutaneous; SE, standard error; W, week.
非 KM Figure
Figure 5Figure 5 Mirikizumab is associated with durable maintenance of (A) clinical remission and (B) endoscopic remission over 4 years (NRI, mNRI, OC). The modified intent-to-treat population was used with NRI, mNRI, and OC methods for missing data. The N for 2 years is lower because some study sites were not included in the interim DBL-1 that were included in DBL-2 (3 years) and the final DBL-3 (4 years). Remitters: MMS SF of 0 or SF of 1 with a ≥1-point decrease from baseline; RB of 0; and ES of 0 or 1. Endoscopic remission: ES of 0 or 1 (excluding friability). Abbreviations: CI, confidence interval; DBL, database lock; ES, endoscopic subscore; HEMR, histologic-endoscopic mucosal remission; mNRI, modified nonresponder imputation; MMS, modified Mayo score; N , number of patients; NRI, nonresponder imputation; OC, observed case; RB, rectal bleeding; SF, stool frequency; W, week.
非 KM Figure
Figure 6Figure 6 Proportions of W52 Maintenance Remitters off CS at (A) 2 years, (B) 3 years, and (C) 4 years; and proportions of W52 Maintenance Remitters off CS who achieved outcomes based on LUCENT-1 induction baseline CS use status (yes vs no) at (A) 2 years, (B) 3 years, and (C) 4 years of continuous treatment. Clinical remission, endoscopic remission, and symptomatic remission at 2, 3, and 4 years for W52 Maintenance Responders without CS use at W52 of continuous mirikizumab treatment (W40 of LUCENT-2). Remitters: MMS SF of 0 or SF of 1 with a ≥1-point decrease from baseline; RB of 0; and ES of 0 or 1. Endoscopic remission: ES of 0 or 1 (excluding friability). Symptomatic remission: SF of 0 or SF of 1 with a ≥1-point decrease in MMS from baseline, and RB of 0. Abbreviations: CI, confidence interval; CS, corticosteroid; ES, endoscopic subscore; MMS, modified Mayo score; N , number of patients; NRI, nonresponder imputation; RB, rectal bleeding; SF, stool frequency; OC, observed case; W, week.
非 KM Figure
Figure 7Figure 7 Mirikizumab maintains rates of clinical remission, CSF remission, endoscopic remission, HEMR, bowel urgency remission, symptomatic remission, and disease clearance at 4 years of continuous treatment in (A) Extended Induction W52 Maintenance Remitters and (B) Extended Induction W52 Maintenance Responders (NRI, mNRI, OC). Remitters: MMS SF of 0 or SF of 1 with a ≥1-point decrease from baseline; RB of 0; and ES of 0 or 1. Responders: ≥30% and ≥2-point decrease from baseline in the composite clinical endpoint of the sum of ES, SF subscore, and RB subscore, and RB of 0 or 1, or a ≥1-point decrease from baseline. CSF remission: clinical remission with no CS use for ≥12 weeks prior to the endpoint of interest. Endoscopic remission: ES of 0 or 1 (excluding friability). HEMR: Geboes score ≤ 2B.0 and ES of 0 or 1 (excluding friability). Bowel urgency remission: Urgency NRS score of 0 or 1. Symptomatic remission: SF of 0 or SF of 1 with a ≥1-point decrease in MMS from baseline, and RB of 0. Disease clearance is defined as achieving symptomatic remission and HEMR. Abbreviations: BU, bowel urgency; CI, confidence interval; CS, corticosteroid; CSF, corticosteroid free; ES, endoscopic subscore; HEMR, histologic-endoscopic mucosal remission; mNRI, modified nonresponder imputation; MMS, modified Mayo score; NRI, nonresponder imputation; NRS, numeric rating scale; RB, rectal bleeding; SF, stool frequency; OC, observed case; W, week.